Alaunos Therapeutics (TCRT) Operating Expenses (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Operating Expenses came in at $1.0 million in Q1 2026, down 7.5% YoY from $1.1 million in Q1 2025, and up 11.21% on a QoQ basis from $910000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Operating Expenses (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Operating Expenses data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Operating Expenses fell 7.5% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 0.6% YoY) and the FY2025 annual result came in at $4.2 million, down 12.28% from the prior year.
- Operating Expenses climbed to $1.0 million in Q1 2026, from $910000.0 in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $11.2 million in Q3 2022 to a low of $759000.0 in Q4 2024.
- A 5-year average of $4.8 million and a median of $1.7 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses plunged 90.45% — and 2025, when it advanced 19.89%.
- Tracing TCRT's Operating Expenses over 5 years: stood at $8.5 million in 2022, then declined by 6.82% to $8.0 million in 2023, then sank by 90.45% to $759000.0 in 2024, then advanced by 19.89% to $910000.0 in 2025, then advanced by 11.21% to $1.0 million in 2026.
- The last three Operating Expenses figures came in at $1.0 million (Q1 2026), $910000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 952,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 910,000.00 |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 759,000.00 |
| Sep 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 7.95 Mn |
| Sep 30, 2023 | 8.66 Mn |
| Jun 30, 2023 | 7.99 Mn |
| Mar 31, 2023 | 9.67 Mn |
| Dec 31, 2022 | 8.53 Mn |
| Sep 30, 2022 | 11.18 Mn |
| Jun 30, 2022 | 9.23 Mn |
| Mar 31, 2022 | 9.09 Mn |
| Dec 31, 2021 | 11.05 Mn |
| Sep 30, 2021 | 22.69 Mn |
| Jun 30, 2021 | 22.64 Mn |